![IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter](https://s3.amazonaws.com/jnswire/jns-media/d3/3d/2595609/dysport.jpg)
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter
![AbbVie : FDA Approves Expanded BOTOX Label for the Treatment of Pediatric Patients with Spasticity | World Pharma Today AbbVie : FDA Approves Expanded BOTOX Label for the Treatment of Pediatric Patients with Spasticity | World Pharma Today](https://www.worldpharmatoday.com/wp-content/uploads/2020/07/botox.jpg)
AbbVie : FDA Approves Expanded BOTOX Label for the Treatment of Pediatric Patients with Spasticity | World Pharma Today
![FDA Approves Expanded BOTOX® Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity | News | Spinal Cord Injury Zone! FDA Approves Expanded BOTOX® Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity | News | Spinal Cord Injury Zone!](https://spinalcordinjuryzone.com/wp-content/media/botox-injection.png)
FDA Approves Expanded BOTOX® Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity | News | Spinal Cord Injury Zone!
![Using Botox to Treat Chronic Pain Conditions, including Osteoarthritis, Joint Pain, and Peripheral Neuropathy Using Botox to Treat Chronic Pain Conditions, including Osteoarthritis, Joint Pain, and Peripheral Neuropathy](https://www.practicalpainmanagement.com/sites/default/files/images/2020/02/04/Table%201.jpg)